CAR-T Cell Therapy
When a doctor first mentions CAR-T, most families have the same questions. What actually happens, and when? How long will we be away from home? What do we need to watch for? CAR-T is one of the few cell therapies that is approved and follows a set path, so these questions have real answers.
This page lays that path out as a calendar, from the first referral to the years of follow-up, so you and the people supporting you can plan each step.
Start here
Where are you on the CAR-T path?
CAR-T in One Minute
CAR-T uses your own immune cells, called T cells. They are collected from your blood, sent to a laboratory and given a new receptor, the “CAR”, that helps them find a marker on cancer cells. Millions of these trained cells are grown, then returned to you through a drip. Inside your body, they seek out and attack the cancer.
CAR-T is an immune cell therapy, not a stem cell therapy. It is a one-time infusion, but the full process takes weeks and needs a specialist cancer centre. See how it differs from stem cell treatments
Who CAR-T Is For
CAR-T is approved for certain blood cancers, usually when the cancer has come back or did not respond to earlier treatment. For some lymphomas it can now be used after only one earlier treatment. These are the products approved in the United States:
| Product | Approved for |
|---|---|
| Kymriah (tisagenlecleucel) | Acute lymphoblastic leukemia in patients up to age 25, large B-cell lymphoma, follicular lymphoma |
| Yescarta (axicabtagene ciloleucel) | Large B-cell lymphoma, follicular lymphoma |
| Tecartus (brexucabtagene autoleucel) | Mantle cell lymphoma, acute lymphoblastic leukemia in adults |
| Breyanzi (lisocabtagene maraleucel) | Large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma |
| Abecma (idecabtagene vicleucel) | Multiple myeloma |
| Carvykti (ciltacabtagene autoleucel) | Multiple myeloma |
Approvals change often and differ by country. Your cancer team, or the FDA list of approved cell and gene therapies, will have the current details.
Often considered
A person with one of the blood cancers above that has come back or stopped responding, who is fit enough for the side effects and has a caregiver available.
Needs careful review
Someone with heart, lung or kidney problems, an active infection, cancer in the brain, or very low blood counts. Older age alone does not rule CAR-T out.
Research only
Solid tumours such as breast, lung or brain cancer, and autoimmune diseases. These are being studied in clinical trials, not offered as standard care.
Related condition: Stem cell and cell therapy for cancer
The CAR-T Calendar
Exact timings depend on the product, your cancer and your treatment centre. This is the usual shape of the journey. “Day 0” is the day the cells are given back to you.
Referral and assessment
A specialist centre confirms CAR-T suits you. You have blood tests, scans and heart and lung checks, and meet the team who will look after you.
Where. At home and the centre
Your T cells are collected
You are connected to a machine that draws blood, keeps the white cells and returns the rest. This is called leukapheresis and takes a few hours. It feels like a long blood donation.
Where. At the centre
Your cells are made in a laboratory
Your cells travel to a lab where they are given their new receptor and multiplied. This usually takes a few weeks. Many people have “bridging” treatment during this time to keep the cancer in check.
Where. Usually at home
Preparing your body
You receive a short course of chemotherapy, usually over about three days. It lowers your existing immune cells to make room for the CAR-T cells.
Where. At the centre
Infusion day
Your CAR-T cells are given back through a drip, much like a blood transfusion. It is usually over quickly. Many people feel well on the day itself.
Where. At the centre
The close-watch period
This is when the main side effects are most likely. The team checks you often, sometimes in hospital. In the US, you must stay close to the treatment centre for at least two weeks after infusion and should not drive during this time.
Where. Near the centre
Recovering and rebuilding
Energy slowly returns. Blood counts may stay low for a while, so infections are a concern. You may need transfusions, antibiotics or treatments that replace antibodies.
Where. Mostly at home
First results
Scans and tests show how the cancer has responded. Your doctor will explain what the results mean for you.
Where. Centre and home
Long-term follow-up
You will have regular check-ups, and childhood vaccines often need repeating. Because CAR-T cells are genetically changed, long-term follow-up for many years is part of the plan.
Where. Your local team and the centre
Plan these before you start
- ☐ A caregiver who can be with you around the clock in the first weeks
- ☐ Somewhere to stay close to the treatment centre
- ☐ Transport, since you should not drive for a while after infusion
- ☐ Time off work or school, for you and your caregiver
- ☐ A list of your medicines and a contact for your home doctor
CAR-T Cell Therapy Success Story
CAR-T cell therapy has provided remarkable success stories, transforming the lives of patients who had exhausted conventional treatment options. Here is one notable example:
The Caregiver Warning Card
CAR-T has two main side effects that can appear suddenly in the first weeks. Caregivers often spot them first. Keep this card where you can see it, and keep the treatment centre’s emergency number with it.
✂ Keep this card
Call the treatment team straight away if you notice
Signs of cytokine release syndrome
- Fever or chills
- Dizziness or feeling faint
- Fast heartbeat
- Trouble breathing
- Severe tiredness or muscle aches
Signs of nerve and brain effects
- Confusion or acting unlike themselves
- Trouble speaking, reading or writing
- Shaking or unsteadiness
- Unusual sleepiness
- A seizure
Tip. Ask the patient to write a short sentence each morning. A change in handwriting can be an early sign of nerve effects.
Both side effects are well known to CAR-T teams, who treat them with specific medicines. That is why you stay close to the centre at first. Acting quickly makes a real difference.
Other Risks to Discuss With Your Team
Infections
Low blood counts and low antibody levels can last for months, so infections need quick attention.
Low blood counts
You may need transfusions or medicines to help your blood recover.
New cancers
Rarely, a new blood cancer has been reported after CAR-T. This is one reason follow-up continues for years.
Questions to Ask Your CAR-T Team
- Which CAR-T product do you recommend for me, and why?
- How long will it take to make my cells, and what treatment will I have while I wait?
- Will I be in hospital after infusion, or staying nearby?
- Who do we call, day or night, if we notice warning signs?
- How will you share my records with my doctor at home?
- What happens if my cells cannot be made, or the treatment does not work?
- What follow-up will I need in the years ahead?
Questions Patients Ask
Is CAR-T a stem cell treatment?
No. It uses T cells, which are immune cells. It is sometimes grouped with stem cell treatments because both are cell therapies.
Is CAR-T a one-time treatment?
The infusion is usually given once. The whole process, including preparation and recovery, takes several months.
Can CAR-T be done abroad?
Approved CAR-T products are given only at certified specialist centres. Some countries also run their own CAR-T programmes and trials. Because of the close-watch period and long follow-up, plan carefully how care will continue when you return home.
Can CAR-T treat solid tumours?
Not yet as standard care. It is being studied in clinical trials for solid tumours.
Planning CAR-T Treatment
A PlacidWay patient coordinator can help you gather the information you need about specialist centres, timelines and follow-up before you decide.
Request InformationReferences
- U.S. Food and Drug Administration, Approved Cellular and Gene Therapy Products
- National Cancer Institute, CAR T-Cell Therapy Infographic
- Leukemia and Lymphoma Society, CAR T-Cell Therapy Timeline
- OncLive, FDA Removes REMS Programs for Approved CAR T-Cell Therapies
- ACGT Foundation, Approved CAR T Therapies
This page is for general information and is not medical advice. CAR-T must be planned and given by a specialist cancer team. Consult your doctor about your own situation.
Who stands behind this article
Health content should never be anonymous. Here are the people who wrote and checked it, with credentials you can verify independently.
Hina Munawar
Patient Care Writer
This author specializes in global healthcare trends and medical education. By focusing on evidence-based practices and a patient-first approach, they provide accessible resources to help readers understand their international treatment options with clarity.
Stem Cell Therapy, Longevity & Regenerative Medicine Specialist
Dr. Alejandro Fernando is a Mexico City-based physician and medical content reviewer focused on stem cell therapy, regenerative medicine, cellular therapy and longevity medicine. His reviewer profile lists medical and postgraduate training related to regenerative medicine, cellular therapy and stem cell biology.
How this article was checked
Table of Contents
